Compare MCFT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | DCTH |
|---|---|---|
| Founded | 1968 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 350.7M |
| IPO Year | 2015 | N/A |
| Metric | MCFT | DCTH |
|---|---|---|
| Price | $18.90 | $10.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $22.20 | ★ $22.60 |
| AVG Volume (30 Days) | 123.5K | ★ 486.6K |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | 0.03 |
| Revenue | ★ $287,846,000.00 | $79,603,000.00 |
| Revenue This Year | $9.21 | $131.69 |
| Revenue Next Year | $8.78 | $39.22 |
| P/E Ratio | ★ $23.35 | $292.70 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $14.39 | $8.12 |
| 52 Week High | $23.94 | $18.23 |
| Indicator | MCFT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 54.49 |
| Support Level | $19.33 | $9.98 |
| Resistance Level | $19.63 | $10.37 |
| Average True Range (ATR) | 0.52 | 0.38 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 14.95 | 36.36 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.